Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008474 | 0.88 | NAMPT (0.52) | MLLT1NAMPTADORA2ACHRM4KDM4E | |
| Hydrochloric Acid SCHEMBL5012099 | 0.87 | NAMPT (0.51) | MLLT1NAMPTADORA2ACHRM4KDM4E | |
| SCHEMBL19002497 | 0.83 | HPGD (0.56) | MLLT1NAMPTADORA2ACHRM4KDM4E | |
| SCHEMBL13732315 | 0.82 | NAMPT (0.57) | MLLT1NAMPTCYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL1685921 | 0.82 | MLLT1 (0.55) | MLLT1NAMPTADORA2ACHRM4KDM4E | |
| SCHEMBL19002500 | 0.81 | CYP3A4 (0.51) | CYP3A4CYP2C19L3MBTL1FAAHEPHX2 | |
| SCHEMBL27596803 | 0.81 | NAMPT (0.53) | MLLT1NAMPTCYP2C19ADORA2ACHRM4 | |
| SCHEMBL23847789 | 0.79 | NAMPT (0.58) | MLLT1NAMPTADORA2ACHRM4KDM4E | |
| SCHEMBL19002539 | 0.79 | EPHX2 (0.49) | CYP3A4CYP2C19L3MBTL1EPHX2 | |
| SCHEMBL19318506 | 0.78 | ADORA2A (0.51) | MLLT1NAMPTADORA2ACHRM4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MLLT1 1240/4885NAMPT 440/4885CYP3A4 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.